Drug intelligence / Profile preview

MR16-1

Development stage: Preclinical
Lead developer: Chugai Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

**MR16-1** is a rat-derived monoclonal antibody that specifically targets the mouse interleukin-6 receptor (IL-6R). It functions as an antagonist by blocking the binding of IL-6 to its receptor, thereby inhibiting IL-6-mediated signaling pathways. MR16-1 is widely used in preclinical research to elucidate the pathophysiological role of IL-6 in various mouse disease models, including autoimmune disease, cardiac hypertrophy, fibrosis, aortitis, neuropathic pain, muscle regeneration, nephritis, and models of CNS and inflammatory disorders. It acts via immune modulation and is not intended for use in humans.

Other names: rat anti-mouse IL-6R antibodyanti-mouse IL-6 receptor antibody

Targets

IL-6R (Interleukin-6 receptor subunit alpha)

Beyond the preview

Go deeper on MR16-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MR16-1.

Explore the full profile